Editas Medicine Inc (EDIT) Receives a Hold from J.P. Morgan


J.P. Morgan analyst Cory Kasimov maintained a Hold rating on Editas Medicine Inc (EDIT) yesterday and set a price target of $30. The company’s shares closed yesterday at $24.63.

According to TipRanks.com, Kasimov is a 3-star analyst with an average return of 2.2% and a 42.6% success rate. Kasimov covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Inc., BioMarin Pharmaceutical Inc., and ACADIA Pharmaceuticals Inc.

Editas Medicine Inc has an analyst consensus of Moderate Buy, with a price target consensus of $42.25.

See today’s analyst top recommended stocks >>

Based on Editas Medicine Inc’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $29.25 million. In comparison, last year the company had a GAAP net loss of $38.72 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR); and CRISPR associated protein 9 (Cas9).

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts